September 1, 2022 — The gout medicine allopurinol has failed to reduce the primary endpoint of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death in patients with ischaemic heart disease, acco

August 31, 2022 — Medtronic plc, a global leader in healthcare technology, announced it has entered into a strategic partnership with BioIntelliSense, a continuous health monitoring and clinical intelligence company, for the exclusive U.S.

August 31, 2022 — Science has long shown that men are at greater risk for developing atrial fibrillation (AFib) than women; but it has never been fully understood why women would be protected from developing the condition.

August 31, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), fully automated and normalized body composition analysis of abdominal CT has promise to augment

August 30, 2022 —  Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest integrated cardiology solutions at the European Society of Cardiology (ESC) Congress (August 26-29, Barcelona, Spain).

August 30, 2022 — A pill containing aspirin and medications to lower lipids and blood pressure more effectively prevents further adverse cardiovascular events after a heart attack compared with taking the drugs separately.

August 30, 2022 — Abbott announced new late-breaking data that show its HeartMate 3 heart pump extends survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling later stage disease.

August 29, 2022 — Detailed results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) significantly reduced the composite of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fracti

August 29, 2022 — Medtronic plc announced that its investigational EV ICD System – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now